Solubility enhancement of cox-2 inhibitors using various solvent systems

Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med. 1997;103(6A):25–35.

Needleman P, Isakson PC. The discovery and function of cox-2. J Rheumatol. 1997;24(suppl 49):6–8.

Bolten WW. Scientific rationale for specific inhibition of cox-2. J Rheumatol. 1998;25(suppl 51):2–7.

Depre M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ. Pharmacokinetics, cox-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol. 2000;56:167–174.

Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89:7384–7388.

Silas S, Clegg DO. Selective cox-2 inhibition. Bull Rheum Dis. 1999,40(2):1–4.

Ran Y, Zhao L, Xu Q, Yalkowsky H. Solubilization of cyclosporin A. AAPS PharmSciTech. 2001;2(1) article 2.

Yalkowsky SH, Roseman TJ. Solubilization of drugs by cosolvents. In: Yalkowsky SH, ed. Techniques of Solubilization of Drugs. Vol 12. New York, NY: Marcel Dekker Inc; 1981:91–134.

Zhao L, Li P, Yalkowsky SH. Solubilization of fluasterone. J Pharm Sci. 1999;88:967–969.

Vavia PR, Adhage NA. Inclusion complexation of nimesulide with ∃-cyclodextrins. Drug Dev Ind Pharm. 1999;25:543–545.

Piel G, Pirotte B, Delneuville I, Neven P, Llabres G, Delarge J, Delattre L. Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysin-cyclodextrin complexes. J Pharm Sci. 1997;86:475–480.

Chowdary KPR, Hymavathi R. Enhancement of dissolution rate of meloxicam. Indian J Pharm Sci. 2001;63(2):150–154.

Baboota S, Agarwal SP. Inclusion complexes of meloxicam with ∃-cyclodextrin. Indian J Pharm Sci. 2002;64(4):408–411.

Wilkinson SG. Alcohols. In: Stoddart JF, ed. Comprehensive Organic Chemistry. Vol. 1. New York, NY: Pergamon Press, 1979;579–706.

Li P, Zhao L, Yalkowsky SH. Combined effect of cosolvent and cyclodextrin on solubilization of non-polar drugs. J Pharm Sci. 1999;88:1107–1111.

Yalkowski SH, Rubino JT. Solubilization of cosolvents 1: organic solutes in propylene glycol-water mixtures. J Pharm Sci. 1985;74:416–421.

Etman MA, Salama RO, Shamsedeen MA, El-Kamal A. Indian. J Pharm Sci. 2001;63(6):459–467.

Millard JW, Alvarez-Nunez FA, Yalkowsky SH. Int J Pharm. 2002;245:153–166.

Krishna G, Hodnick WF, Lang W, Lin X, Karra S, Mao J, Almassian B. Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP 40101M. AAPS PharmSciTech 2001;2(3) article 14.

Powell M, Nguyen T, Baloian L. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998;52:238–311.

Mottu F, Laurent A, Rufenacht D, Doelker E. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J Pharm Sci Technol. 2000;54:456–469.